Annabel Maruani, Elsa Tavernier, Olivia Boccara, Juliette Mazereeuw-Hautier, Sophie Leducq, Didier Bessis, Laurent Guibaud, Pierre Vabres, Virginie Carmignac, Stéphanie Mallet, Sébastien Barbarot, Christine Chiaverini, Catherine Droitcourt, Anne-Claire Bursztejn, Céline Lengellé, Jean-Baptiste Woillard, Denis Herbreteau, Anne Le Touze, Aline Joly, Christine Léauté-Labrèze, Julie Powell, Hélène Bourgoin, Valérie Gissot, Bruno Giraudeau, Baptiste Morel
IMPORTANCE: Sirolimus is increasingly being used to treat various vascular anomalies, although evidence of its efficacy is lacking. OBJECTIVE: To assess the efficacy and safety of sirolimus for children with slow-flow vascular malformations to better delineate the indications for treatment. DESIGN, SETTING AND PARTICIPANTS: This multicenter, open-label, observational-phase randomized clinical trial included 59 children aged 6 to 18 years with a slow-flow vascular malformation who were recruited between September 28, 2015, and March 22, 2018, in 11 French tertiary hospital centers...
November 1, 2021: JAMA Dermatology